Skip to content

MapLight Therapeutics, Inc.

MPLT

CIK 0001770069 · Pharmaceutical Preparations · Nasdaq

  • Alvarado Therapeutics, Inc. (until 2019-03-22)
← back to feed
Revenue (TTM)
—
Q1 Mar 2026
Net Income (TTM)
−$142.27M
−107.7% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$92.93
+82.4% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
—
Q1 Mar 2026
Net Margin
—
Q1 Mar 2026
Free Cash Flow (TTM)
−$138.61M
Q1 Mar 2026
Cash
$55.71M
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
42.44M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings